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INTRODUCTION 
 
 
Atopic dermatitis is a common chronic inflammatory disease of childhood with a 
significant burden on patients and caregivers (1). It is estimated that the prevalence of AD 
is around 10 – 20% in the developed where it is believed to have plateaued, whereas in 
developing countries it is of lower prevalence, but on the rise (2). It is known that most 
cases (up to 60%) of AD appear during the first year of life (3). Although most cases tend 
to resolve within the first few years, some may persist into adulthood. In addition even 
cases that resolve early tend to leave behind hypersensitive skin and may also relapse (4). 
In addition, the dual exposure to allergen hypothesis suggests that tolerance to antigens 
occurs in the neonate through high-dose oral exposure and allergen sensitization occurs 
through low-dose cutaneous exposure (5). This makes AD a risk factor for developing food 
allergies later on in life. Therefore to prevent early development and sequelae of AD, it is 
important to understand the triggers that set-off the disease process.  
 The skin in AD is characterized by several abnormalities in barrier function 
including altered lipid composition, decreased number of tight junctions, altered protease 
activity and altered antimicrobial activity, leaving the skin prone to microbial infection and 
allergen sensitization (6). Nonetheless, little is known about the initial changes that 
specifically occur in keratinocytes, which are the key players in barrier function.  
MicroRNAs (miRs), which are short (~22 nucleotides) non-coding RNAs, are 
mainly involved in post-transcriptional gene regulation (7). MiRs have been implicated in 
the pathogenesis of many diseases including allergic diseases (8, 9).  Therefore, in this 
study, we aimed to find the early miR dysregulation seen in infants who later developed 
AD and look at their effect on keratinocytes. 
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METHODS 
 
CHIBA (Chiba HIgh risk Birth cohort for Allergy) study 
A birth cohort study of newborn infants with a family history of allergic disease was set up 
in Seikei-kai Chiba Medical Center and Chiba University Hospital in Chiba, one of the 
prefectures around the Tokyo region, from January 2010 to December 2011. This study 
protocol was approved by the Bioethics Review Committee, Faculty of Medicine, Chiba 
University, Japan (approval number 754). 
 
Study participants 
The study was advertised by use of a poster at the above hospitals and all women attending 
the above hospitals who were at 34 weeks of gestation, who, whose partner, and/or their 
children had any allergic diseases such as atopic dermatitis, asthma, allergic rhinitis, and/or 
food allergies were invited to participate in the study. 
The eligibility criteria were: 
a. Japanese ethnicity 
b. Parent/s and/or sibling/s of the expected child has one or more allergic diseases 
c. Not having or expected to have any severe congenital abnormalities such as 
congenital heart disease 
The mothers and their expected babies were enrolled in the study after obtaining informed 
consent. Following the birth of the study subjects, we reconfirmed the subject’s eligibility, 
and there were no babies excluded due to congenital abnormalities. We did not exclude 
babies having any perinatal abnormalities. The guardians were requested by letter to take 
the study subjects to each clinic at 1 month, 6 months, 1 year, and 2 years of age for 
physical examinations. 
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Perinatal information 
Perinatal information such as gestational age at birth, birth weight, mode of delivery, and 
APGAR scores was obtained from medical records of the mothers. 
 
Questionnaires 
At 1 month, 6 months, 1 year, and 2 years of age, the guardians of the study subjects were 
interviewed about the health of their children (symptoms or a diagnosis of allergic 
diseases), breast-feeding, exposure to second-hand tobacco smoke at home, and exposure to 
dogs or cats. Diagnosis of wheezing was made by history of 3 or more episodes of 
wheezing or by the subject’s family doctor. Diagnosis of both allergic rhinitis and food 
allergies was made by the subject’s family doctor. 
 
Physical examination 
Physical examinations were performed at 1 month and 6 months of age, by Dr. Naoki 
Shimojo at Chiba University Hospital or by Dr. Hiroko Suzuki at Seikei-kai Chiba Medical 
Center. Diagnosis of infantile face eczema was made by physical examination and/or by the 
history of itchy eczema on the face by 6 months of age. 
Physical examination of all participants was repeated 1 year and 2 years of age, by Dr. 
Naoki Shimojo at Chiba University Hospital, and a diagnosis of AD was made using the 
guidelines for management of AD by Japanese Dermatological Association.. 
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Blood sampling 
Blood samples were collected from the mothers at 36 weeks of gestation and cord blood, 
and blood samples at 1 year and 2 years of age were collected from the infants. The serum 
samples were stored at -30ºC within 24 h until measurement of allergen-specific IgEs. 
 
Allergen-specific IgE assay 
Levels of specific IgEs to Dermatophagoides farinae (Derf), cat dander and Japanese cedar 
pollen in the mothers’ sera and those to egg white, milk, Derf, cat dander and Japanese 
cedar pollen in umbilical cord serum and the children’s sera at 1 and 2 years of age were 
measured by ImmunoCAP®. A specific IgE level > 0.7 UA/mL was considered positive. 
 
Cell culture  
Neonatal Human Primary Epithelial Keratinocytes (HPEKs) were obtained from 
CELLnTEC Advanced Cell Systems AG (Bern, Switzerland). The cells were cultured in 
CnT-Prime medium (CELLnTEC #CNT-PR). 
All cells tested negative for Mycoplasma. 
 
MiRNA transfection and house dust mite (HDM) stimulation of HPEKs 
 A human miR-144 mimic (C-300612-05-0002), a miRNA positive control for GAPDH 
(CP-001000-02-05) and a miRNA negative control (CN-001000-01-05) were purchased 
from Dharmacon (Horizon Discovery, UK). HPEKs were transfected with miRNAs using 
the LipofectamineTM  RNAiMAX Transfection Reagent (Invitrogen, USA) following the 
manufacturer’s instructions. Briefly, HPEKs were seeded to reach 60-80% confluency at 
transfection. For triplicates on a 24-well plate, the LipofectamineTM  RNAiMAX reagent 
was diluted in 50 µl of Opti-MEM® medium (Gibco) and added to 3 µl of  the 10 mM 
miRNA diluted in 50 µl Opti-MEM® so that the final amount of miRNA in each well was 5 
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pmol. Cells were incubated with the miRNAs for 24-48 hours, stimulated with 25 µg/ml of 
HDM (Torii Pharmaceutical Co. Ltd, Japan) for a further 24 hours and then used for qPCR 
and immunostaining. 
 
 Total RNA extraction and qPCR 
Total RNA was extracted from serum using the miRNeasy Serum/Plasma Kit (Qiagen, 
Hilden, Germany). The initial screening of samples for candidate miRNAs was done using 
the Exiqon Serum/Plasma Focus microRNA PCR Panel, 96-well (V4.MI) which 
contains assays for 179 individual microRNAs (Exiqon, Denmark). Total RNA was 
extracted from all cell types using the miRCURY™ RNA Isolation Kit – Cell & Plant 
(Exiqon, Denmark). Complementary DNA was synthesized using SuperScript® III First-
Strand Synthesis SuperMix (Invitrogen, USA) and real-time PCR was performed using the 
QuantiTect SYBR Green PCR kit (Qiagen, Germany) on a CFX Connect Real-Time 
System (Bio-Rad).  
 
Fluorescence microscopy and filipin staining for cholesterol 
HPEKs were grown to 60-70% confluence on glass coverslips and fixed in 4% 
paraformaldehyde for 10 minutes. The cells were permeabilized with 0.3% saponin for 20 
minutes, washed and blocked with 3% BSA in PBS for 1 hour. The cells were stained 
overnight with a 1:200 dilution of rabbit polyclonal antibodies to ABCA1 (ab7360, Abcam, 
UK). Goat polyclonal Alexa Fluor® 488-conjugated antibodies to rabbit IgG (ab150077, 
Abcam, UK) were used as secondary antibodies at a 1:300 dilution for 1 hour of staining. 
Staining for cholesterol was done for a further 30 minutes with a working solution of 0.05 
mg/ml Filipin III (CAS 480-49-9, Cayman Chemical, USA) dissolved in DMSO and 
diluted in PBS. Imaging was done on a Keyence BZ-X700 (Keyence, Japan). 
NF-κB p65 subunit translocation inhibition assay 
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HPEKs were grown on coverslips as for fluorescence microscopy as mentioned above. 
Forty-eight hours following transfection, the cells were co-incubated for 24 hours with 25 
µg/ml of HDM extract and 15 nmol of NK-κB p65 inhibitor JSH-23 (Calbiochem®, Merck, 
Germany). The cells were stained overnight with a 1:200 dilution of rabbit monoclonal 
antibodies to the NF- κB p65 subunit (#8242, Cell Signaling Technology, USA). Goat 
polyclonal Alexa Fluor® 488-conjugated antibodies to rabbit IgG (ab150077, Abcam, UK) 
were used as secondary antibodies at a 1:300 dilution for 1 hour of staining. Cells were 
stained with 300 nM solution of DAPI for 5 minutes. Imaging was done on a Keyence BZ-
X700 (Keyence, Japan). 
 
Statistical analysis 
Statistical analysis was done on GraphPad Prism® 6.0f. PLS analysis was done on JMP® 
Pro 12.0.1. All data are shown as mean ± SEM. Mann-Whitney Test and the Wilcoxon test 
were used for comparison of groups. P less than 0.05 was considered significant. All results 
shown are from 3 independent experiments. 
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RESULTS 
 
Cord blood miR-144 is elevated in children who develop AD at 1 year of age 
 
To identify the miRNA changes that are seen in the maternal serum (MS) and the umbilical 
cord serum (CS) of children with AD, we selected a nested case-control population of 36 
children who did (AD) or did not develop AD (No AD) at 1 year of age and their mothers 
by propensity score matching. The baseline characteristics of the infants and their mothers 
in the nested case-control population were similar to those of the cohort population (tables 
1 and 2).   
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Table 1. Baseline characteristics of the infants and their mothers in the cohort 
population and the nested case-control population defined by propensity score 
matching 
Maternal age, parity, BMI, gestational age, and birth weight were all compared by 
Student’s t-test, and serum total IgE levels by Mann-Whitney test. Other variables were 
compared by Pearson’s χ2 test 
   
 Cohort population 
(n=268)                 
Mean (± SD), % 
Study population 
(n=36) 
 Mean (± SD), % 
P value 
Maternal characteristics     
Age 33.51 (±4.67) 34.25 (±4.66) 0.357 
Parity 1.55 (±0.71) 1.64 (±0.87) 0.769 
History of AD 25.0 27.8 0.688 
History of other allergic 
diseases 
86.6 83.3 0.608 
BMI before pregnancy 21.43 (±3.16) 21.6 (±2.83) 0.502 
BMI during pregnancy 25.06 (±3.12) 25.29 (±2.96) 0.577 
Total IgE 210.87 (±508.29) 104.94 (±135.07) 0.213 
Affected by AD 1.5 2.8 0.470 
Affected by bronchial asthma 2.2 8.3 0.078 
Infant characteristics    
Gender (girls) 50.4 41.7 0.377 
Cesarean section 29.5 30.6 1.000 
Gestational age (weeks) 38.88 (±1.39) 38.61 (± 1.23) 0.180 
Birth weight (g) 3026 (±360.76) 3023.00 (±317.47) 0.830 
Total IgE at birth 0.74 (±1.53) 0.4 (±0.46) 0.051 
Total IgE at 1 year 45.22 (±84.56) 46.92 (±75.63) 0.849 
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Table 2. Baseline characteristics of nested case control population 
 
Infants 	  Mothers 
Case ID Gender Gestational age (weeks) 
Birth 
weight 
(g) 
Total IgE 
(IU/mL) AD 	  
Maternal 
age (y) 
History 
of AD 
History of 
allergic 
disease 
AD Asthma Total IgE (IU/mL) 
             
C019 Boy 37 2710 0.32 +  40 - + - - 305.0 
C038 Girl 39 2848 0.19 -  26 - + - - 12.8 
C051 Boy 38 2660 0.09 -  36 - + - - 2.5 
C052 Girl 38 3180 0.64 +  31 - + - - 136.0 
C062 Boy 41 3244 0.08 +  36 - + - - 6.8 
C066 Boy 38 3012 1.34 +  30 + + + - 80.4 
C069 Girl 39 2956 0.10 +  26 + + - - 11.3 
C070 Boy 38 3380 0.13 -  35 - + - - 10.0 
K007 Boy 38 2952 0.04 -  40 - - - - 2.5 
K008 Girl 38 3190 0.26 +  25 - + - + 62.5 
K013 Boy 39 2706 1.98 +  39 - - - - 48.4 
K032 Boy 39 3082 0.28 +  31 - - - - 87.8 
K040 Boy 36 2464 0.31 -  37 - + - - 31.1 
K045 Boy 38 2412 0.29 -  36 - + - - 131.0 
K059 Girl 38 2990 0.04 -  38 + + - - 9.6 
K074 Girl 40 2912 0.18 +  33 + + - - 48.0 
K078 Boy 36 3110 0.45 +  39 - + - - 104.0 
K079 Boy 38 3390 0.10 -  38 - + - - 13.2 
K083 Girl 39 2642 0.04 -  30 + + - - 13.6 
K085 Boy 39 3712 0.70 +  39 - - - - 123.0 
K095 Boy 39 2984 0.13 +  36 - + - - 11.4 
K102 Boy 40 3508 0.30 -  35 - - - - 144.0 
K107 Boy 38 3522 0.50 -  42 + + - - 187.0 
K112 Boy 38 2604 0.25 +  30 - + - - 126.0 
K132 Boy 40 3202 0.17 +  38 - + - - 42.3 
K138 Boy 37 3274 0.22 +  27 + + - - 113.0 
K144 Boy 41 3536 0.11 +  34 - + - + 27.6 
K146 Girl 37 2802 0.30 -  30 - + - + 304.0 
K180 Girl 40 2890 0.62 -  28 - + - - 688.0 
K196 Girl 39 2832 0.04 +  40 - - - - 2.5 
K197 Girl 40 3190 0.23 +  37 + + - - 104.0 
K199 Girl 39 2940 0.65 -  39 - + - - 255.0 
K205 Girl 40 3468 0.26 -  36 - + - - 14.2 
K207 Girl 38 2770 1.15 -  35 + + - - 313.0 
K209 Boy 38 2904 1.67 -  31 + + - - 165.0 
K228 Girl 40 2850 0.16 -  30 - + - - 41.4 
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In the 36 selected subjects, we analyzed the expression profile of 179 miRs. By use of 
partial least squares regression, we identified the miRs that were related to the development 
of AD at 1 year. Candidate miRs with a VIP score of 1.5 or more were selected for further 
evaluation (table 3). 
 
Table 3. MicoRNAs in umbilical cord serum (CS) and maternal serum (MS) 
associated with the development of AD at 1 year. Partial least squares regression was 
used to identify miRNAs associated with the development of AD at 1 year of age. The 
miRs in CS and MS with a VIP score over 1.5 were selected as candidates for further 
analysis. 
	  miRNA in the CS (n=36) 	  ΔCq value (mean ± SD) 
	  VIP value VIP SE Coefficient 	  AD (n=18) Non-AD (n=18) 
	  	  	  	  	  	  	  	  	  	  	  
miR_361_3p 2.512  1.726  0.046  	  8.466  ± 0.986  7.622  ± 0.536  
miR_144_3p 2.500  0.811  -0.037  	  -1.185  ± 0.331  -0.741  ± 0.494  
miR_195_5p 2.484  1.706  0.043  	  10.164  ± 2.882  7.935  ± 0.858  
miR_150_5p 2.257  0.733  0.039  	  1.466  ± 0.669  0.835  ± 0.689  
miR_423_3p 2.191  1.405  0.042  	  1.551  ± 0.322  1.283  ± 0.273  
miR_146b_5p 1.816  0.826  0.028  	  5.747  ± 0.636  5.300  ± 0.606  
let_7i_5p 1.803  0.515  0.034  	  1.996  ± 0.228  1.996  ± 0.228  
miR_30d_5p 1.758  1.934  0.024  	  4.752  ± 0.472  4.456  ± 0.377  
miR_107 1.749  1.398  -0.030  	  0.814  ± 0.175  0.988  ± 0.309  
miR_500a_5p 1.732  1.143  -0.030  	  6.643  ± 0.648  7.366  ± 1.351  
miR_151a_3p 1.717  2.235  0.014  	  4.288  ± 0.428  4.001  ± 0.423  
miR_200c_3p 1.706  1.556  0.039  	  8.468  ± 2.519  7.227  ± 0.722  
miR_16-2_3p 1.699  1.518  0.025  	  3.754  ± 0.562  3.369  ± 0.593  
miR_191_5p 1.688  1.618  0.025  	  1.681  ± 0.302  1.458  ± 0.369  
miR_532_3p 1.682  0.521  -0.020  	  4.191  ± 0.366  4.446  ± 0.407  
let_7g_5p 1.678  0.866  0.021  	  0.948  ± 0.384  0.700  ± 0.371  
miR_181a_5p 1.660  1.341  0.022  	  2.594  ± 0.463  2.324  ± 0.361  
miR_342_3p 1.648  1.038  0.028  	  2.058  ± 0.550  1.652  ± 0.702  
miR_133a 1.593  1.996  -0.032  	  8.671  ± 1.151  10.039  ± 2.895  
miR_505_3p 1.575  1.178  0.028  	  4.805  ± 0.462  4.461  ± 0.646  
miR_335_5p 1.544  2.076  0.018  	  6.669  ± 0.705  6.279  ± 0.592  
miR_376a_3p 1.510  2.177  0.025  	  4.801  ± 0.601  4.393  ± 0.781  
miR_605 1.509  2.093  -0.033  	  8.927  ± 1.327  9.598  ± 0.935  
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The miR expression analysis of the 36 sera by qPCR showed that miR-144 was 
significantly higher in the CS of children who developed AD at 1 year of age. This 
difference was not observed in MS at 36 weeks of gestation or in the children at 1 year of 
age (Fig 1). We did not find any correlation between miR expression in MS and CS, 
suggesting that the miRs in MS may not have a direct effect on babies (Fig 2). We found 
that the miR-144 expression in CS was not associated with total IgE levels at 1 year of age 
(Fig 3). As this suggests that miR-144 may play a role in the pathogenesis of AD 
independent of atopy, we focused on the role of miR-144 in keratinocytes.  
	  miRNA in the MS (n=36) 	  ΔCq value (mean ± SD) 
	  VIP value VIP SE Coefficient 	  AD (n=18) Non-AD (n=18) 
	  	  	  	  	  	  	  	  	  	  	  
miR_301a_3p 2.854  1.594  0.051  	  3.835  ± 0.602  3.034  ± 0.665  
miR_133b 2.732  0.713  -0.054  	  6.106  ± 0.976  9.384  ± 3.774  
miR_133a 2.676  1.019  -0.049  	  5.572  ± 1.192  9.007  ± 4.028  
miR_424_5p 2.407  0.538  0.031  	  2.421  ± 0.638  1.770  ± 0.656  
miR_27b_3p 2.256  1.341  0.030  	  1.106  ± 0.561  0.590  ± 0.549  
miR_485_3p 2.196  0.437  0.020  	  4.960  ± 0.859  4.149  ± 0.946  
miR_148b_3p 2.146  0.760  0.031  	  1.597  ± 0.418  1.279  ± 0.300  
miR_142_3p 1.992  0.749  0.021  	  -0.009  ± 0.530  -0.471  ± 0.622  
miR_101_3p 1.943  0.547  0.017  	  -0.094  ± 0.693  -0.548  ± 0.449  
miR_15a_5p 1.937  0.967  0.020  	  -2.700  ± 0.375  -2.995  ± 0.386  
miR_296_5p 1.933  0.914  -0.025  	  8.126  ± 3.826  11.298  ± 4.370  
miR_128 1.912  1.230  0.018  	  2.018  ± 0.388  1.706  ± 0.428  
miR_21_5p 1.866  0.984  0.010  	  -3.049  ± 0.615  -3.409  ± 0.306  
miR_141_3p 1.854  1.329  0.019  	  5.498  ± 2.701  3.998  ± 1.006  
miR_30d_5p 1.812  1.902  0.028  	  4.828  ± 0.475  4.463  ± 0.541  
miR_191_5p 1.785  0.715  -0.019  	  1.495  ± 0.564  1.832  ± 0.374  
miR_320a 1.780  1.126  0.017  	  0.221  ± 0.569  -0.160  ± 0.516  
miR_154_5p 1.775  0.892  -0.029  	  8.173  ± 3.880  11.122  ± 4.515  
miR_382_5p 1.766  1.037  -0.026  	  7.050  ± 2.941  9.668  ± 4.429  
miR_126_3p 1.654  1.024  0.010  	  -1.341  ± 0.650  -1.761  ± 0.649  
miR_215 1.654  0.630  0.016  	  2.621  ± 0.761  2.075  ± 0.920  
miR_375 1.626  1.334  0.027  	  5.251  ± 2.724  3.848  ± 1.528  
miR_766_3p 1.618  1.255  -0.018  	  6.211  ± 2.376  8.413  ± 4.318  
let_7i_3p 1.539  0.918  0.025  	  9.650  ± 3.562  7.721  ± 2.850  
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Figure 1. MiR-144 levels are elevated in the cord serum of infants who developed AD 
at 1 year of age. MiR-144 levels were estimated in CS, MS and serum at 1 year of age 
using quantitative RT-PCR. MiR-144 expression was significantly increased in the CS of 
the AD group. This difference was not seen in the MS or serum at 1 year of age. **P < 
0.005, Mann-Whitney test. AD n = 18; No AD n = 18. CS, cord serum; MS, maternal 
serum; AD, atopic dermatitis. 
 
 
 
 
 
Umbilical cord serum (CS)                     1 year 
								 	
Maternal serum (MS)                    
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Figure 2. MiRs in maternal serum (MS) and cord serum (CS) are not correlated.  
Levels of 179 miRs in MS and CS were measured by qPCR. The levels of each miR did not 
show any correlation between MS and CS. The data shows 2 representative miRs including 
miR-144, which was investigated further in this study.  
 
 
          
Figure 3. MiR-144 levels in cord serum are not related to the total IgE levels in serum 
at 1 year of age. The miR-144 levels in cord serum were plotted against the Serum total 
IgE levels at 1 year of age. There was no correlation between the levels. 
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ABCA1 is a target of miR-144 
 
Using the commercially available software microRNA.org (10), TargetScan (11) 
and miRBase (12), we identified ATP-binding cassette transporter A1 (ABCA1) as a target 
of miR-144. ABCA1 is involved in cholesterol efflux from cells and miR-144 has been 
shown downregulate ABCA1 expression leading to cholesterol accumulation within cells 
(13, 14). To observe the effect of miR-144 on the expression of ABCA1 in keratinocytes, 
we transfected human epithelial keratinocytes with miR-144 and looked at the expression 
of ABCA1. MiR-144 transfected cells showed decreased ABCA1 mRNA (Fig 4A) and 
protein levels (Fig 4B). Keratinocytes also showed the accumulation of cholesterol 
following miR-144 transfection (Fig 4B).  
 
House dust mite (HDM) stimulation of miR-144 transfected keratinocytes leads to 
increased translocation of the NF-κB p65 subunit 
 
ABCA1 knockout in macrophages has been shown to cause cholesterol 
accumulation and exaggerated cytokine response to the TLR agonists (15). This 
exaggerated response is believed to be due to the enhanced recruitment of all MyD88-
dependent TLRs (TLR 2, 4, 7 and 9) into lipid rafts leading to enhanced downstream 
signaling and pro-inflammatory cytokine production through NF-κB and activator protein-1 
(AP-1) signaling (15, 16). Therefore, we looked at how miR-144 transfected keratinocytes 
with decreased ABCA1 expression responded to house dust mite (HDM) stimulation, 
which is a well know trigger of inflammation in AD. With HDM stimulation miR-144 
increased the nuclear translocation of the NF-κB p65 subunit (Fig 5).  
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Figure 4. MiR-144 transfection decreases ABCA1 expression in HPEKs. (A) MiR-144 
transfection decreased the mRNA levels of ABCA1. (B) HPEKs grown in media only or 
transfected with miR-144 for 24 and 48 hours. Cells were stained with Alexa Fluor 488 for 
ABCA1 (green) and filipin for cholesterol (blue). MiR-144 transfection caused a decreased 
in ABCA1 expression leading to cholesterol accumulation within cells. HPEKs, human 
primary epithelial keratinocytes.  
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Figure 5. MiR-144 induces nuclear translocation of NF-κB p65 subunit translocation. 
HDM induced the nuclear translocation of p65 (green). This was enhanced when miR-144 
was introduced into the HPEKs prior to HDM stimulation. The p65 translocation was 
abrogated by JSH-23 (p65 translocation inhibitor). The nucleus is stained in blue with 
DAPI. 
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HDM stimulation of miR-144 transfected keratinocytes leads to increased mRNA 
expression of human beta-defensin 2 (hBD-2) 
 
As we did not see any pro-inflammatory cytokine production from keratinocytes in 
response to NF-κB activation, we looked at other molecules that play a role in the 
pathogenesis of AD via NF-κB activation. Anti-microbial peptides (AMPs) are small 
cationic peptides present in epithelia that show direct anti-microbial activity and have also 
been shown to play a role in antigen presentation, cytokine release and the recovery of 
barrier function (17, 18). The AMPs implicated in AD include the inducible beta defensins 
hBD-2 and 3, and the cathelicidin LL-37. Although some studies show a decreased 
production of AMPs in AD, others show an increased secretion in acute compared to 
chronic lesions (19, 20). In addition, hBDs are known to induce the production of pro-
inflammatory cytokines from keratinocytes and act as chemo-attractants for mast cells, 
inducing the release of pruritogenic mediators and increasing vascular permeability (21-
23). In fact, hBD 2 levels were shown to be significantly higher in the lesional stratum 
corneum compared to non-lesional skin and that the levels correlate with SCORing of 
Atopic Dermatitis (SCORAD) scores and trans-epidermal water loss (TEWL) (24). We did 
observe that miR-144 transfected HPEKs, when stimulated with HDM extract, significantly 
increased the mRNA expression of hBD-2. The levels decreased when the transfected cells 
were co-incubated with HDM and the NF-κB inhibitor JSH-23 (Fig 6). Human beta-
defensin 3 and LL-37 mRNA levels did not change significantly in response to HDM 
stimulation. As NF-κB activation has been shown to increase hBD-2 production, the 
significant increase in hBD-2 mRNA levels that we observed may be a consequence of the 
NF- κB activation (25). 
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Figure 6. MiR-144 increases HDM-induced hBD-2 expression in keratinocytes. HPEKs 
were transfected with miR-144 for 48 hours and stimulated with 25 µg/ml of HDM extract 
for a further 24 hours with or without 15 nmol of p65 translocation inhibitor, JSH-23. The 
mRNA levels of hBD2, hBD3 and cathelicidin LL-37 were quantified by qPCR. HBD-2 
showed a significant increase in expression following HDM stimulation. *P < 0.05, 
Kruskal-Wallis test. Data shown are from 3 independent experiments. HDM, house dust 
mite. 
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DISCUSSION 
 
MiRs are increasingly being investigated for their role in disease pathogenesis and 
as biomarkers. In spite of this, there is still a dearth of knowledge about the actual roles that 
miRs may have in allergic diseases. In this study we found that miR-144 is higher in cord 
blood of infants who developed AD at 1 year of age. MiR-144 targets ABCA1 and miR-
144 transfection into keratinocytes decreased the expression of ABCA1 leading to the 
accumulation of cholesterol. MiR-144-induced cholesterol accumulation has been shown to 
induce pro-inflammatory cytokine production in THP-1 macrophages (13). However, we 
did not detect any significant change in TNF-α, TSLP, IL-25, IL-17A, IL-17F or IL-33 
levels in serum, or the mRNA levels in transfected keratinocytes (data not shown). In 
addition, TNF-α was undetectable in the culture supernatants of transfected keratinocytes.  
In psoriasis, another chronic inflammatory skin disease, cholesterol accumulation 
has also been shown to promote IL-17A signaling in keratinocytes (26). IL-17A, the 
signature cytokine of Th17 cells, is expressed highly in early-onset pediatric AD skin 
lesions as opposed to normal and adult AD skin, along side the increase in other related 
molecules including LL-37 (27). Although we did not find any cytokine changes in the 
serum, the changes may be visible in early AD skin itself. There is also an increasing body 
of evidence that identifies the role of cationic peptides in non-IgE-mediated stimulation of 
mast cells (28). Our finding that miR-144 did not correlate with serum IgE levels also 
supports the fact that the early skin barrier dysfunction may be assisted by mast cell-
derived cytokines such as IL-31.  This may suggest that the initial activation may come 
from the resident innate immune cells of the skin.  
Our study is limited in several aspects: we conducted this study on the premise that 
miR-144 targets keratinocytes. We did not investigate any change in miRs or other 
downstream molecules in skin specimens of infants due to the inability to obtain samples. 
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Also, we have only looked at the keratinocyte response to HDM: it is worthwhile 
investigating the response to Staphylococcus aureus, which has a prominent role in the 
pathogenesis of AD.  
Nevertheless, at present there is little knowledge about the earliest triggers that 
initiate barrier damage in AD. To prevent the onset of this predominantly childhood disease, 
it is essential to identify and if possible, remedy them. Therefore, we believe that our 
primary finding that miR-144 is elevated in the umbilical cord blood provides an important 
clue to the understanding of what prompts early-life AD and adds a new dimension to the 
understanding of this disease.  
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